Literature DB >> 8621897

Regulation of the Fas lytic pathway in cloned CTL.

A Glass1, C M Walsh, D H Lynch, W R Clark.   

Abstract

Cloned murine CTL activated via the TCR or by PMA and ionomycin up-regulate surface Fas ligand and show an increased ability to kill non-Ag-specific Fas+ target cells. This up-regulation starts after 45 to 60 min and has a t1/2 for reversal of about 90 min. Up-regulation of lytic function is accompanied by up-regulation of Fas ligand on the CTL surface, which can be blocked by protein synthesis inhibitors. When up-regulation of Fas lytic function was induced by PMA and ionomycin, EGTA blocked both activation of lytic function and expression of Fas ligand detected by FACS analysis. However, when up-regulation was induced by specific Ag, EGTA blocked activation of lytic function, but not up-regulation of Fas ligand. Moreover, EL-4 cells have very high levels of surface Fas ligand, although they are not cytotoxic. Thus, expression of surface Fas ligand may be required, but not sufficient, for Fas-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Significance of Fas and Fas ligand in tuberculous lymphadenitis.

Authors:  Tehmina Mustafa; Stanley J Mogga; Sayoki G M Mfinanga; Odd Mørkve; Lisbet Sviland
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

2.  The regulation of FasL expression during activation-induced cell death (AICD).

Authors:  T Nguyen; J Russell
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

3.  Ca2+ signaling modulates cytolytic T lymphocyte effector functions.

Authors:  M T Esser; D M Haverstick; C L Fuller; C A Gullo; V L Braciale
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

4.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

5.  Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells.

Authors:  A L Wagelie-Steffen; K Hartmann; H Vliagoftis; D D Metcalfe
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

Review 6.  T cell-tumor cell: a fatal interaction?

Authors:  D B Chappell; N P Restifo
Journal:  Cancer Immunol Immunother       Date:  1998-10       Impact factor: 6.968

7.  Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer.

Authors:  Guang-Zhou Wu; Chun-Xia Pan; Dong Jiang; Qiang Zhang; Yin Li; Shi-Ying Zheng
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

8.  The expression of selected proapoptotic molecules in dermatitis herpetiformis.

Authors:  Zebrowska Agnieszka; Erkiert-Polguj Anna; Wagrowska-Danilewicz Malgorzata; Danilewicz Marian; Sysa-Jedrzejowska Anna; Anna Cynkier; Waszczykowska Elzbieta
Journal:  Clin Dev Immunol       Date:  2012-06-20

9.  The Distribution of Human Stem Cell-like Memory T Cell in Lung Cancer.

Authors:  Hai Hong; Yong Gu; Si Yuan Sheng; Chuan Gang Lu; Jian Yong Zou; Chang You Wu
Journal:  J Immunother       Date:  2016 Jul-Aug       Impact factor: 4.456

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.